预约演示

更新于：2025-01-23

Krukenberg Tumor

Krukenberg瘤

更新于：2025-01-23

基本信息

别名

Cancer metastatic to ovary、Carcinoma, Krukenberg、Krukenberg Carcinoma

+ [36]

简介

Mucocellular carcinoma of the ovary, usually metastatic from the gastrointestinal tract, characterized by areas of mucoid degeneration and the presence of signet-ring-like cells. It accounts for 30%-40% of metastatic cancers to the ovaries and possibly 1%-2% of all malignant ovarian tumors. The lesions may not be discovered until the primary disease is advanced, and most patients die of their disease within a year. In some cases, a primary tumor is not found. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1685)

关联

项与 Krukenberg瘤相关的药物

Sabizabulin

靶点

Tubulin

作用机制

微管蛋白抑制剂

在研机构

Veru, Inc. [+1]

原研机构

The Ohio State University

在研适应症

新型冠状病毒感染 [+4]

非在研适应症

Krukenberg瘤 [+11]

最高研发阶段申请上市

首次获批国家/地区-

首次获批日期1800-01-20

NP-G2-044

靶点

fascin

作用机制

fascin抑制剂

在研机构

Novita Pharmaceuticals, Inc.

原研机构

Cornell University [+1]

在研适应症

实体瘤

非在研适应症

乳腺癌 [+12]

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

Curcumin/Doxorubicin

姜黄素/多柔比星

靶点

DNA x Top II

作用机制

DNA嵌入剂 [+1]

在研机构

Immix Biopharma Australia Pty Ltd [+2]

原研机构

Immix Biopharma, Inc.

在研适应症

晚期恶性实体瘤 [+6]

非在研适应症

Krukenberg瘤 [+1]

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

项与 Krukenberg瘤相关的临床试验

NCT05143970

/ Recruiting临床1期IIT

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.
The trial will be conducted in two parts, Part I- Dose escalation: This part aims to identify the maximum tolerated dose (MTD) of IPH5301 agent in monotherapy and recommended phase 2 dose (RP2D) for future trials, followed by a safety expansion study part cohort.
Part II- Expansion cohort: A total of 12 HER2+ cancer patients, respectively 6 breast cancer patients and 6 gastric cancer patients, is planned to be enrolled into the next expansion cohort to select a recommended dose of IPH5301 to be administered in combination with chemotherapy and trastuzumab for evaluation in future trials with selected advanced solid tumors.

开始日期2022-01-21

申办/合作机构

Institut Jean Paoli & Irene Calmettes

[+1]

NCT05001282

/ Terminated临床1/2期

Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors

This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available.

开始日期2021-09-13

申办/合作机构

Elucida Oncology, Inc.初创企业

CTRI/2020/08/027025

/ CompletedN/A

A multicenter, open label, randomized, balanced, two-treatment, three-period, three-sequence, single dose, replicate cross-over bioequivalence study of Doxorubicin Hydrochloride Pegylated Liposome Injection 2mg/mL (50 mg/m2 dose) of Sun Pharmaceutical Industries Ltd., India with that of Caelyx® 2mg/mL [Doxorubicin Hydrochloride (Pegylated Liposomal)] concentrate for solution for infusion of Janssen Pharmaceutica NV, Belgium in stable advanced ovarian cancer patients who have failed a first-line platinum based chemotherapy regimen or stable metastatic breast cancer patients under fed (standardized light meal) condition. - NA

开始日期2021-03-19

申办/合作机构

Sun Pharmaceutical Industries Ltd.

100 项与 Krukenberg瘤相关的临床结果

登录后查看更多信息

100 项与 Krukenberg瘤相关的转化医学

登录后查看更多信息

0 项与 Krukenberg瘤相关的专利（医药）

登录后查看更多信息

1,073

项与 Krukenberg瘤相关的文献（医药）

2025-01-15·The Journal of Maternal-Fetal & Neonatal Medicine4区 · 医学

Krukenberg tumor in pregnancy: a rare case and review of the literature

4区 · 医学

Review

作者: Cruciat, Gheorghe ; Kovacs, Tunde ; Mureșan, Daniel ; Nemeti, Georgiana ; Eniu, Dan T. ; Preda, Andreia ; Surcel, Mihai ; Goidescu, Iulian G.

Krukenberg's tumor diagnosed in pregnancy is an uncommon situation that raises both diagnosis and medical management issues. We performed a review of the existing literature regarding this pathology, diagnostic means and therapeutic approaches, motivated by a case in our own practice. A 35-year-old primigravida was diagnosed with an adnexal mass during the first trimester prenatal ultrasound. Ultrasound revealed a 10 cm right adnexal mass with multiple septae, richly vascularized, whose presence and characteristics were confirmed by magnetic resonance imaging. Due to the progressively increasing tumor size, laparoscopy was performed with right adnexectomy and peritoneal biopsies. Histopathology diagnosed a metastatic ovarian tumor from a mucinous colorectal adenocarcinoma. After delivery the patient was further investigated and diagnosed with sigmoid cancer. Even though ovarian cancer in pregnancy is rare, adnexal ultrasound is mandatory when scanning during the first trimester to rule out the presence of associated fallopian or ovarian masses.

2025-01-01·International Journal of Pharmaceutics

Tumor specific delivery and radiation-enhanced tumor penetration of mesoporous silica nanoparticles for effective radionuclide therapy of ovarian peritoneal metastasis

Article

作者: Carrasco-Rojas, Natalia ; Bolch, Wesley E ; Dawson, Robert J ; Lu, Xiuling ; Goodwin, Cameron ; Lin, Xinhao ; Hargrove, Derek ; Brown, Amy ; Katugampola, Sumudu ; Salner, Andrew ; Ranjbar, Sheyda ; Nam, Sangho ; Jay, Michael ; Howell, Roger W ; Darji, Mittal

Advanced ovarian cancer with peritoneal metastasis is challenging to treat. Limited tumor delivery and penetration of the therapeutics to deep tumor regions are significant barriers to effective treatment. The rising radiopharmaceuticals offer hopes for patients through targeted delivery. However, site specific delivery avoiding off target effect remain critical and challenging. We have developed radioactive ¹⁶⁶Holmium loaded mesoporous silica nanoparticles (¹⁶⁶Ho-MSNs) that exhibited predominant accumulation to peritoneal metastases of ovarian cancer upon intraperitoneal administration. It was observed that fluorescence labeled radioactive ¹⁶⁶Ho-MSNs distributed throughout the tumor tissues, while non-radioactive fluorescent ¹⁶⁵Ho-MSNs showed mainly tumor surface deposition of MSNs. The deep penetration leads to uniform therapeutic radiation distribution and absorbed doses within tumors as demonstrated by the dosimetry analysis. The radiation dosing regimen consisting of two 100 µCi ¹⁶⁶Ho-MSN doses separated by 7 days decreased tumor activity and increased the overall lifespan and ascites free survival in several models of IP tumor-bearing mice. These findings illustrate that ¹⁶⁶Ho-MSN is promising for the treatment of ovarian peritoneal metastasis, with selective targeting advantage of the nanoparticles and limited off-target radiation exposure.

2024-12-01·Clinical Nuclear Medicine

Diagnostic Challenges in Invasive Mole With 18F-FDG PET/CT

Article

作者: Kitano, Yurika ; Nakamoto, Yuji ; Shimamura, Takuto ; Minami, Akihiko ; Nakamoto, Ryusuke

AbstractA 34-year-old woman underwent 18F-FDG PET/CT scan following a diagnosis of an invasive mole. Although CT indicated multiple lung metastases, FDG uptakes were not evident. In contrast, FDG uptakes were observed in the pelvic lesion including the left ovary, suggestive of ovarian metastasis. MRI disclosed a ring-shaped enhancement typical of a corpus luteum. This corpus luteum was supposed to be maintained by the elevated human chorionic gonadotropin excreted from the invasive mole. This case underlines the importance of careful interpretation of 18F-FDG PET/CT in the evaluation of invasive moles, highlighting potential false positive in corpus luteum.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

来和芽仔聊天吧

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。